Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 183

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 183
---
 associated with acute toxicity when delivered freely in the circulation, however, has been found to be highly effective as an ADC payload due to its ability to improve the overall efficacy and toxicity of the ADC. Multiple companies are utilizing pure exatecan or exatecan derivatives in their ADC platforms. Deruxtecan (“DXd”), for example, has been shown to have potent anti-tumor efficacy with an improved safety profile compared to pure exatecan. Trastuzumab deruxtecan (“T-DXd”),an ADC consisting of a humanized mAb trastuzumab (Herceptin) covalently linked to DXd, is approved for treatment of breast cancer, gastric cancer and gastroesophageal adenocarcinoma and sold by Daiichi Sankyo. Our payload has similar structure, cytotoxicity and preclinical safety profile to DXd. - 120 -

Our Product Candidates

| * | Anticipated timing, subject to IND approval, as applicable. |

| 1. | JAMA Oncol. 2021;7(12):1824-1832. |

| 2. | SEER data |

| 3. | https://www.ncbi.nlm.nih.gov/books/NBK482458/. |

| 4. | JAMA Oncol. 2017;3(10):1335-1342. |

PTK7-CPT113 Overview

| Our lead product candidate PTK7-CPT113 is a next wave ADC with a DAR of 6 targeting PTK7 that we plan to                                                                                                                                     |
| develop for the treatment of non-small cell lung cancer (“NSCLC”) and platinum resistant                                                                                                                                                     
 ovarian cancer (“PROC”), with potential to expand into other indications. We believe PTK7-CPT113 has the potential to be among the first in next wave ADCs with a TOPO1 inhibitor payload to enter the clinic. With its optimized linker and 
 TOPO1 inhibitor payload, we hope to improve upon the initial ORRs seen with cofetuzumab pelidotin (“Cofe-p”), a first generation MMAE-based ADC with a DAR 4 targeting PTK7.                                                                 
 PTK7-CPT113 has shown superior cytotoxic activity compared to a first generation                                                                                                                                                             
 MMAE-based PTK7 ADC in both in vitro and in vivo preclinical models. We are currently completing IND-enabling studies and expect to submit an IND for the use of PTK7-CPT113 in treating                                                     
 solid tumors